Macrophage-Encapsulated Bioorthogonal Nanozymes for Targeting Cancer Cells

JACS Au. 2022 Jul 7;2(7):1679-1685. doi: 10.1021/jacsau.2c00247. eCollection 2022 Jul 25.


Macrophages migrate to tumor sites by following chemoattractant gradients secreted by tumor cells, providing a truly active targeting strategy for cancer therapy. However, macrophage-based delivery faces challenges of cargo loading, control of release, and effects of the payload on the macrophage vehicle. We present a strategy that employs bioorthogonal “nanozymes” featuring transition metal catalysts (TMCs) to provide intracellular “factories” for the conversion of prodyes and prodrugs into imaging agents and chemotherapeutics. These nanozymes solubilize and stabilize the TMCs by embedding them into self-assembled monolayer coating gold nanoparticles. Nanozymes delivered into macrophages were intracellularly localized and retained activity even after prolonged (72 h) incubation. Significantly, nanozyme-loaded macrophages maintained their inherent migratory ability toward tumor cell chemoattractants, efficiently killing cancer cells in cocultures. This work establishes the potential of nanozyme-loaded macrophages for tumor site activation of prodrugs, providing readily tunable dosages and delivery rates while minimizing off-target toxicity of chemotherapeutics.

PMID:35911454 | PMC:PMC9327086 | DOI:10.1021/jacsau.2c00247


Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

Generated by Feedzy